F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comAlivus Life Sciences Ltd is an emerging pharmaceutical and healthcare company known for its strong product pipeline, robust financial performance, and rapid expansion within the domestic and global markets. With a focus on formulations, research-driven products, and market reach, the company has built investor confidence over time. In this article, we will analyze the current share performance of Alivus Life Sciences Ltd and forecast its share price targets from 2025 to 2030.
This article discusses Alivus’s business fundamentals, shareholding structure, and year-wise target prices based on its market trends and growth potential.
Below are the latest key details of the stock based on recent market data:
| Detail | Value |
|---|---|
| Open | ₹892.90 |
| Previous Close | ₹872.05 |
| Volume | 1,50,004 |
| Value (Lacs) | ₹1,327.39 |
| VWAP | ₹884.42 |
| Beta | 0.80 |
| Market Capitalization | ₹10,856 Cr |
| High | ₹893.00 |
| Low | ₹873.00 |
| UC Limit | ₹1,046.45 |
| LC Limit | ₹697.65 |
| 52-Week High | ₹1,251.00 |
| 52-Week Low | ₹850.00 |
| Face Value | ₹2 |
| All Time High | ₹1,335.10 |
| All Time Low | ₹370.00 |
A beta of 0.80 indicates lower volatility compared to the broader market, making Alivus Life Sciences Ltd relatively stable for medium- to long-term investors.
Alivus Life Sciences Ltd operates in the pharmaceutical and life sciences domain with a strong presence across India and select global markets. The company is engaged in the development, manufacturing, and marketing of high-demand healthcare products. It focuses heavily on R&D, operational efficiency, and new product launches, helping it maintain strong momentum in a competitive sector.
Key highlights:
Extensive portfolio in formulations and healthcare solutions
Strong market capitalization and investor confidence
Consistent focus on innovation and research
Lower volatility with stable price movements
Expanding distribution and export channels
| Investor Type | Holding (%) |
|---|---|
| Promoters | 74.91% |
| Retail and Others | 12.78% |
| Foreign Institutions | 6.84% |
| Mutual Funds | 3.87% |
| Other Domestic Institutions | 1.60% |
A promoter holding of 74.91% reflects strong commitment from the company’s leadership, which is often seen as a positive sign for long-term investors.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2025 | 920 | 980 |
| 2026 | 990 | 1,080 |
| 2027 | 1,100 | 1,220 |
| 2028 | 1,230 | 1,360 |
| 2029 | 1,350 | 1,520 |
| 2030 | 1,520 | 1,720 |
These targets are based on growth factors such as product expansion, revenue performance, R&D efficiency, past price trends, and market stability.
In 2025, Alivus is expected to show modest growth supported by stable financial performance.
Reasons:
Increased market reach in major therapy categories
Lower volatility due to beta of 0.80
Strong promoter confidence
Investment Outlook: Suitable for SIP-based entry or accumulation during dips.
By 2026, improved operational efficiency and expanding product pipeline may drive the stock price upward.
Reasons:
Steady sales from chronic and acute segments
Brand visibility in domestic and export markets
Support from retail and institutional investors
Investment Outlook: Good for medium-term portfolios.
The company may experience accelerated growth due to expanding market share and better margins.
Reasons:
New product approvals
Market leadership in select therapeutic areas
Consistent quarterly performance
Investment Outlook: Encouraging for growth-focused investors.
By 2028, Alivus may enter a more robust expansion phase.
Reasons:
Strengthened R&D investments
Wider penetration in international markets
Improved EBITDA margins
Investment Outlook: Long-term investors may see strong compounding benefits.
Growth may remain strong as Alivus becomes more competitive in the pharma sector.
Reasons:
Consistent earnings growth
Higher demand for specialty medicines
Better market positioning
Investment Outlook: Suitable for investors targeting long-term wealth creation.
By 2030, Alivus Life Sciences Ltd may achieve significant milestones, pushing its valuation higher.
Reasons:
Large-scale expansion
Strong promoter backing
Sustainable revenue and profit growth
Investment Outlook: Considered a strong candidate for long-term holdings with high potential returns.
Alivus Life Sciences Ltd has emerged as a promising stock within the pharmaceutical sector. Its strong promoter holding, stable financial performance, and expanding market presence make it attractive for long-term investors.
Reasons to consider investing:
Good stability with lower volatility
Strong promoter confidence
Growth-oriented business model
Consistent performance across financial years
Risks to consider:
Pharma sector dependency on regulatory approvals
High competition from domestic and international companies
Market sensitivity to global healthcare trends
Always consult a financial advisor before making final investment decisions.
Alivus Life Sciences Ltd has shown impressive growth in market valuation and business operations. With a 52-week low of ₹850 and a 52-week high of ₹1,251, the stock displays steady momentum supported by solid fundamentals.
Based on its performance and future prospects, the share price of Alivus Life Sciences Ltd may reach between ₹1,520 and ₹1,720 by 2030. Long-term investors looking for stable and growth-oriented opportunities may find this stock a strong candidate.
Register & Login